One mechanism attributed to drug refractoriness in epilepsy is overexpression of the efflux transporters like P-glycoprotein at the BBB, which extrudes anti-seizure drugs back into the blood, therefore resulting in sub-therapeutic drug levels at the site of the epileptic focus (64). This evidence concerns the gene ABCB1 and epilepsy.